Figure S6 from Transfer of Damaged Mitochondria from Cancer Cells to Cancer-Associated Fibroblasts Promotes Tyrosine Kinase Inhibitor Tolerance in EGFR-Mutant Lung Cancer
Figure S6. RGS5+MYL9+ CAFs facilitate drug-tolerant persister (DTP) formation and tumor regrowth after Osimertinib withdrawal. (A-B) Colony formation assays demonstrate enhanced proliferative recovery of (A) HCC827 and (B) PC9 cells co-cultured with RGS5+MYL9+ CAFs compared to RGS5+MYL9+-d CAFs controls following cyclic Osimertinib treatment (2 μM, 9 days) and withdrawal (n=3). Experiments were performed using paired CAF subsets isolated from three treatment-naïve EGFR-mutant LUAD patients. The primary CAF subsets utilized in this figure were isolated from patients 13 to 15. Relevant clinical characteristics of these patients are summarized in Supplementary Table 1. Data are shown as mean ± SD and were analyzed by a two-tailed unpaired t-test, *P <0.05, **P <0.01, ***P <0.001.